The recognition that adult bone marrow stem cells (BMSCs) 
Introduction
Tissue stem cells have been viewed as multipotential precursor cells capable of producing the differentiated cells specific to the tissue in which they are located. However, in recent years, it has become very clear that adult stem cells exhibit a remarkable plasticity, hitherto unsuspected. The observation that adult hepatocytes, biliary epithelium and endothelial cells within the liver can be derived from BMSCs indicates a potential source of cells to replace the liver mass following injury from a variety of insults. More recently it has been demonstrated that BMSCs can contribute to the formation of kidney cells, including tubular epithelial cells, podocytes, mesangial cells and myofibroblasts. This newly described axis of organ regeneration also provides a potential mechanism of delivering therapeutic genes to the liver and kidney. So far, progress in this field has been characterised by observations made in animal models and tissue analysis from human transplant patients and therefore there are few in vitro data describing the factors that control BMSC differentiation into hepatic or renal cells. Here, we will describe the contribution of BMSCs to organ repair, including some data regarding the embryology of the liver and kidney that help to explain recent observations and indicate directions to look for signals that control stem cell trafficking and transdifferentiation.
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Hepatic differentiation from blood-borne stem cells

Adult liver regeneration
The liver has a well-documented ability to regenerate itself following injury or partial resection. It has long been known that hepatocytes are the major contributors to liver regeneration. 1 However, when liver damage is very severe, or when carcinogens or toxins inhibit hepatocyte expansion, liver progenitor cells called oval cells (so called because they are small cells with little cytoplasm and oval nuclei) can be seen within the liver. 2 The oval cells emerge from the canals of Hering (the point where the terminal bile ducts meet the periportal hepatocytes) and migrate into the hepatic lobule where they can differentiate into hepatocytes or biliary epithelial cells. Until recently it was believed that oval cells were formed only by de-differentiation from biliary epithelial cells, but recent work suggests that a proportion of these oval cells may originate from the bone marrow. 4 who were studying the cell surface markers of oval cells. They found that oval cells expressed Thy-1 and CD34, cell surface markers used to identify haematopoietic stem cells. The question therefore arose as to whether oval cells were derived from circulat-ing haematopoietic stem cells (HSCs) in the adult. This was answered by a series of bone marrow and liver transplant experiments that were performed in conjunction with a protocol to induce oval cell activation. Carbon tetrachloride was given to rats to induce liver necrosis together with 2-acetylaminofluorene thus inhibiting hepatocyte regeneration and stimulating oval cell proliferation. Firstly, bone marrow from male rats was transplanted into lethally irradiated female recipients and Y chromosome-containing liver cells, implying male origin, were detected by in situ hybridization. Secondly, female rats deficient in the enzyme dipeptidyl peptidase IV (DPPIV), received bone marrow transplants from DPPIVpositive male rats. This allowed the immunohistochemical recognition of bone marrow-derived DPPIV positive liver cells by a method independent of Y chromosome detection. Lastly, livers were transplanted from L21-6 antigen negative Brown-Norway rats into L21-6 antigen positive Lewis rats, confirming that cells from a recipient extra-hepatic source could repopulate the donor liver. 5 Similar gender mismatched bone marrow and liver transplant techniques have been applied in a murine model to show that bone marrow cells differentiate into hepatocytes even in the absence of liver damage. 6 This axis of liver regeneration also occurs in humans. Liver biopsy specimens from female patients who had received male bone marrow transplants and male patients who had received female liver transplants were analysed using in situ hybridization for the presence of the Y chromosome. This revealed both hepatocytes and biliary epithelial cells containing the Y chromosome and therefore likely to be of bone marrow origin. The proportion of cells of bone marrow origin was found to be highly variable, with between 1 and 40% of hepatocytes containing the Y chromosome. 7, 8 Biliary epithelial cells can also form from bone marrow (Figure 1a) 
Bone marrow can contribute to liver regeneration
Hepatic endothelial cells
Using the experimental protocol of lethally irradiated female mice receiving male bone marrow transplants and by examining liver biopsies from male patients with female liver grafts, it has been recently shown that a proportion of endothelial cells within the liver contain the Y chromosome and therefore are probably also of bone marrow origin. 10 A proportion of patients who have received liver transplants can be weaned off all immunosuppression, ie become tolerant to their graft. Although the mechanisms of tolerance are complex, replacement of the endothelium with host tissue could be contributing to this phenomenon.
Functionality of bone marrow-derived liver cells
It is now accepted that the BMSCs can differentiate into hepatocytes and biliary epithelial cells, an important question remains: do these BMSC-derived liver cells have the same functional capacity and life cycle as endodermally derived hepatocytes?
Lagasse et al 11 used the fumarylacetoacetate hydrolase (FAH)-deficient mouse (a fatal murine model animal of hereditary tyrosinemia type I) to demonstrate the metabolic capability of these BMSC-derived hepatocytes within the liver. They found that a bone marrow transplant with as few as 50 purified HSCs from metabolically competent donor mice could rescue the FAH mouse from an otherwise fatal metabolic disease of the hepatocyte. They found that only the HSC component of bone marrow had the ability to rescue these animals. In this model, there is a strong stimulus for clonal expansion of the metabolically competent hepatocytes and they found approximately 30% of rescued mouse livers hepatocytes were of HSC origin. In a murine, gender-mismatched bone marrow transplant model it has been shown that the BMSC derived hepatocytes produce albumin mRNA. 6 In liver transplant patients, Alison et al 7 demonstrated that the BMSC-derived hepatocytes were cytokeratin 8 positive. We have also found that following paracetamolinduced liver injury in the mouse the bone marrowderived hepatocytes present in the liver are able to produce appropriate cytochrome P450 enzymes (unpublished observations, Figure 1b) .
What of the life cycle of the bone marrow-derived hepatocyte once differentiation has occurred? Do these cells have a similar life cycle and life span as endogenous hepatocytes or does this vary, perhaps according to the relative age of the donor marrow? We have attempted to answer this question by examining the chromosome complement of the bone marrow-derived hepatocytes. It is known that as hepatocytes within the liver age, they may undergo polyploidization (an increase in the number of chromosomal copies within the nucleus). We have found, by using in situ hybridization for the Y-chromosome, that bone marrow-derived hepatocytes also show multiple chromosomal copies within their nuclei and therefore are likely to be passing through the same life cycle (Figure 1c and d) . BMSC-derived endothelial cells express factor VIII-associated antigen, as do endogenous endothelial cells. 10 
Stem cell trafficking through the liver and differentiation
The signals that direct the recruitment of BMSCs into the liver and directs their differentiation into hepatocytes, biliary epithelium or endothelial cells are not yet understood. Is there a population of bone marrow-derived stem cells that continually traffic through the liver, and is this increased during inflammation or tissue repair following damage? Does mobilization of BMSCs into the periphery (eg by G-CSF) enhance HSC hepatic engraftment in the same way that bone marrow engraftment is enhanced? 12 Embryological studies may give some indication about stem cell homing to the liver. During foetal life haematopoiesis occurs at specific sites that change during foetal maturation. Haematopoiesis initially takes place in the yolk sac, then shifts to the aorta/gonad/mesonephros (AGM) region of the foetus. Pluripotential hepatoblasts reside in the AGM that are able to differentiate into both biliary epithelial cells and hepatocytes. 13 By full-term, haematopoiesis is established in the bone marrow, but diseases that cause bone marrow replacement can cause haematopoiesis to revert to the liver, even in adulthood. One factor known to be important in the stem cell localization to the BM is stroma-derived factor-1 (SDF-1). Mice deficient in the chemokine SDF-1, or its receptor CXCR-4 have normal foetal liver haematopoiesis, but fail to undergo the normal translocation of HSCs to the bone marrow. Furthermore, cells that express high levels of CXCR-4 have increased efficiency of haematopoietic engraftment following BM transplantation.
14 Whether or
Gene Therapy not similar factors act in the adult liver to co-ordinate hepatic engraftment by BMSCs remains to be established. Once BMSCs have engrafted within the liver environment the direction of their differentiation may be dependent upon cell loss or upon signalling from surrounding cells or extracellular matrices. Looking again to embryological studies for clues we find that Oncostatin M is produced by CD45 + haematopoietic cells in the fetal liver and is able to induce the differentiation of hepatoblasts into a metabolically competent adult hepatocyte phenotype. 15 
Renal differentiation from blood-borne stem cells
Recent studies indicate that the bone marrow can contribute to renal turnover and regeneration. We have used in situ hybridization for the Y chromosome in female mice that have received male whole bone marrow transplants to demonstrate the bone marrow origin of a wide range of kidney cell types, including tubular epithelial cells (Figure 1e ), interstitial cells and podocytes. 16 Other groups have found evidence for the mesangial cell differentiation of BMSCs. 17 In our studies, up to 8% of the renal tubular epithelium was found to be of bone marrow origin. As there was no evidence of renal damage in these mice this may represent the baseline contribution of bone marrow to the normal wear-and-tear renewal of the tubular epithelium. We have made similar observations in human biopsy specimens from gender mismatched renal transplants (female kidneys grafted into male recipients). We observed Y-chromosome positive tubular cells ( Figure 1h ) and cells within the glomeruli that appeared to be podocytes. Interestingly, we found a wide variation in the percentage of Y-positive tubular epithelium in the humans (from 0-20%). These biopsies were performed during renal injuries of varying severity, and this may be creating an immune-mediated positive selection pressure on the cells of host origin. Given the three-dimensional complexity of cellular structure within the glomerulus, the identification of extrarenal-derived glomerular cells with apparently gender-mismatched chromosomes using conventional light microscopy, has its limitations. One potential way around this is through the use of confocal microscopy, where three-dimensional reconstructions of these cells can be produced from a series of sequential optical slices (Figure 1g ).
Other workers studying renal biopsies from sex-mismatched renal allografts found mesenchymal cells of host origin in the vascular and interstitial compartments of the kidneys, and suggested that a circulating mesenchymal precursor cell can migrate to areas of inflammation in the kidney. 18 We have also observed Y chromosome-positive cells expressing alpha-smooth muscle actin around Bowman's capsule in male bone marrow transplanted female mice (Figure 1f) , suggesting that the origin of these cells is the bone marrow. There is now experimental evidence in rodents that epithelial cells are capable of transdifferentiation into myofibroblasts. 19 However, given the above findings it is possible that the bone marrowderived cells colonizing the interstitium of the kidney are in fact capable of transdifferentiating directly into tubular epithelium, and podocytes. Krause et al 20 have shown that a purified HSC population engrafted multiple organs. However, no donor-derived renal tubular epithelial cells were seen and glomeruli were not commented upon. It is possible that the absence of stromal stem cells in the bone marrow graft accounts for this difference.
Kidney endothelium
Over 30 years ago, Williams and Alvarez 21 looked for the presence of Barr bodies (a transcriptionally inactivativated condensed X chromosome present in female somatic cells) to identify the origin of cells in a female kidney transplanted into a male patient. They reported that the endothelium of an artery appeared derived from the recipient at 182 weeks after transplantation. Using the same technique, Sinclair 22 reported that in the majority of cross-gender renal grafts no significant endothelial repopulation occurred from the recipient, unless there was significant damage to the vasculature of the graft. Sinclair suggested that extensive, acute damage requires repair by circulating host cells while less severely damaged grafts would be able to restore endothelial continuity from surviving donor tissue.
More recent work has confirmed that the extent of replacement of endothelial cells lining small renal vessels by host is related to the severity of rejection. 23 We have also found occasional male endothelial cells in female kidneys grafted into male recipients, 16 however other groups have reported no evidence of revascularization by the recipient, even in cases where the transplant failed. 24 
The therapeutic potential of stem cells for the liver and kidney
The normal liver is a mitotically quiescent organ and in order to efficiently transduce hepatocytes in vivo with potentially permanent gene therapy vectors, techniques have been used to induce hepatocytes to enter the cell cycle. These include such measures as partial hepatectomy, which are clinically unacceptable, or growth factor injection before the vector administration, which can be relatively inefficient. 25 Ex vivo hepatic gene therapy has been attempted in patients using hepatocytes isolated by partial hepatectomy, which were cultured and transduced with a therapeutic gene ex vivo, before re-introduction via portal vein infusion. 26 However, this technique has been criticized for being technically difficult and potentially hazardous. 27 BMSCs traffic to the liver and kidneys and transdifferentiate into stable cell populations, such as biliary epithelial cells and hepatocytes. Given that this axis of stem cell trafficking appears to persist in the setting of tissue damage, these BMSCs would therefore seem suitable targets for gene therapy. Although the proportion of BMSCderived hepatocytes is small in the normal liver, Lagasse's work 11 has shown that if there is a strong positive selection pressure, a proportion of these hepatocytes can increase.
In theory, one could transduce the stem cells ex vivo and reintroduce them into the body, or attempt to transduce the relevant stem cells within the bone marrow. Since BMSCs are obviously capable of travelling widely within the body and perhaps differentiating into diverse cell types within several organs, there is therefore a need for some mechanism to prevent inappropriate gene expression within these organs. There are several theoretical ways of achieving this specificity of gene expression. Approaches currently under investigation include the partial differentiation of BMSCs ex vivo before reintroduction, and the identification of a specific stem cell population with a propensity to differentiate into the cell type of choice. Obviously, one would need to establish that this does not alter the trafficking and transdifferentiation properties of these stem cells. Another technique being developed is to use tissue-specific promoters to confine gene expression to the target organ, eg once a BMSC has engrafted into the liver and transdifferentiated. However, tissue-specific promoters are not absolutely specific and within a complex biological system there may be a certain amount of 'promoter leak'. There are also several requirements upon any potential gene therapy vectors used for stem cell transduction. The vector should be non-immunogenic, be capable of long-term gene expression and not influence the transdifferentiation of the stem cells. From currently available gene therapy vectors perhaps the lentiviral-based vectors best fit this description.
Specific diseases Inflammatory liver disease
Crosby et al 9 have demonstrated that BMSCs are able to differentiate into biliary epithelia (Figure 1a) , and would therefore seem to offer an excellent route to deliver antiinflammatory genes locally to the bile ducts. This would be attractive for conditions such as primary biliary cirrhosis, where there is local immune-mediated destruction of bile ducts and immunosuppression has often been associated with systemic toxicity. The number of BMSCderived biliary epithelial cells may be a limiting factor for this approach unless it can be increased.
Antiviral gene delivery
Bone marrow-derived hepatocytes have been detected in the livers of patients infected with hepatitis B and C. 2 This may enable the hepatic targeting of antiviral therapeutic genes, such as interferon-alpha. There are several theoretical reasons why BMSCs are an attractive way to deliver antiviral cytokines to the liver. There is evidence that by targeting the antiviral cytokine interferon-alpha to the liver there is an enhanced antiviral effect. 28 Furthermore, by locally delivering an antiviral cytokine one may limit the side-effects that are frequently seen. An important consideration is whether the expression of a therapeutic gene within an undifferentiated HSC may have an effect upon the engraftment or differentiation of that HSC. Encouragingly, transduction of CD34 + cells with the interferon-alpha gene does not appear to inhibit cell proliferation, adhesion molecule expression, or engraftment into NOD/SCID mice. 29 
Liver cirrhosis
The end-product of chronic liver damage is liver cirrhosis. Here there is destruction of the livers normal architecture. The normally quiescent stellate cells are activated to a myofibroblast phenotype and lay down the characteristic bands of connective tissue that surround regenerative hepatocyte nodules. There is a growing awareness based on both animal models of cirrhosis and human studies that the process of liver cirrhosis is not entirely irreversible. For example, in a rat model of cirrhosis produced by dimethylnitrosamine, repeated transductions of the human HGF gene into skeletal muscle inhibited hepatocyte apoptosis, produced a reduction in liver fibrosis and an improvement in the survival rate. 30 However, there are few data at present regarding BMSC trafficking to the cirrhotic liver or the stability of the BMSC progeny within the severely damaged liver.
Gene Therapy
The in vitro production of hepatocytes for artificial liver support There are large numbers of patients with severe liver disease (due to either deterioration of chronic liver disease or acute liver damage), who would benefit from some form of biochemical support for their failing livers. For some considerable time it has been an attractive prospect to produce a bio-artificial liver machine for extracorporeal hepatic support, similar to renal dialysis, but in addition providing the complex synthetic and metabolic functions of the liver. However, at present there are no readily available supplies of large numbers of human hepatocytes for this. BMSCs may be an attractive source of hepatocytes for use in a bio-artificial liver machine. 31 They would be free of the theoretical risks of transmitting unknown infective agents from porcine hepatocytes and are not derived from potentially tumorgenic immortalised cell lines. Clearly if one could identify the factors that control HSC differentiation into hepatocytes perhaps this would enable one to harvest stem cells either from peripheral or cord blood, expand this population in vitro and differentiate these cells into functioning hepatocytes. However, there are still considerable hurdles to be overcome in order to produce sufficient numbers of cells to supply clinical requirements.
Renal diseases
Tubular cell death is a common end-point in both acute and chronic renal disease. Our finding that tubular cells and glomerular podocytes can be bone marrow-derived raises the possibility that renal diseases could be amenable to treatment by bone marrow. This could be applied either to replace the damaged cells with cells derived from bone marrow, or through the use of BMSCs transduced with genes to provide resistance to the disease processes involved. A similar approach has been tested in rodents by Yokoo et al 32 who transplanted BMSCs transduced with an interleukin 1 receptor antagonist into sublethally irradiated recipients. When glomerulonephritis was induced in these mice, these cells trafficked to the glomerulus and a reduction in renal damage was observed.
Podocytes are central to the maintenance of glomerular capillary permeability and are one of the potential therapeutic cellular targets in the kidney. For example, nephrin, a large protein normally present in the podocyte plasma membrane at the filtration slits, is mutated in a range of nephrotic syndromes, including congenital nephropathy of Finnish type. 33 Another potential target for stem cell therapy is Alport's syndrome, where the absence of specific collagen IV chains in renal basement membrane leads to progressive impairment of renal function. 34 
Conclusions
Clearly the newly described axis of tissue regeneration from the bone marrow is of great interest both to the biologist and clinician. Many questions remain to be answered regarding the signals that modulate BMSC mobilization and recruitment into solid organs and subsequent transdifferentiation. Some of these answers may come from the study of developing embryos, where there are tightly controlled shifts in the location of haematopoiesis. Recent commentators have rightly asked for greater proof of function of cells arising from BMSC transdifferentiation. 35 In the liver and kidney, these timely comments are being addressed. There are many potential applications that may be exploited using adult stem cells, including cell support following organ damage, and as vehicles for therapeutic gene targeting to the liver and kidney. However, in order to realise these aims a familiar and not unexpected comment needs to be made: much more research is required.
